Event Synopsis
Artificial intelligence is reshaping drug discovery and digital health at pace. Yet the majority of promising innovations never reach patients. The bottleneck is rarely the science.
This panel cuts through the noise and goes back to basics: who defines the problem, who pays for the solution, and how does it fit within the organisations that need to adopt it? Bringing together perspectives from pharma, healthcare providers, and regulatory authorities, we will examine the structural, cultural, and evidential barriers that determine whether an AI-driven innovation succeeds or…

Hosted by Nucleate Switzerland, Nucleate Luma & Nucleate HQ